World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
113
Citations
71909
World Ranking
4834
National Ranking
475

John D. Hainsworth publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John D. Hainsworth sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 725 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John D. Hainsworth D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John D. Hainsworth sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 113 D-Index — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2014 - Fellow of the American Society of Mechanical Engineers

Overview

John D. Hainsworth is affiliated with the Sarah Cannon Research Institute in the United Kingdom. Their research contributions span multiple areas within medicine, with a focus on oncology and related biomedical sciences.

The fields of study in which Hainsworth has published include Medicine and Biochemistry, Genetics and Molecular Biology. Subfields particularly represented in their work are Oncology, Pulmonary and Respiratory Medicine, Surgery, Molecular Biology, and Cancer Research.

The main research topics addressed by Hainsworth include:

  • Renal cell carcinoma treatment
  • Renal and related cancers
  • Peptidase Inhibition and Analysis
  • Cancer Immunotherapy and Biomarkers
  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Genomics and Diagnostics

They have contributed to publications in well-known scientific venues, including:

  • Cancer Research
  • The Lancet Oncology
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Kidney Cancer Journal

Frequent co-authors in their research include Razelle Kurzrock, Howard A. Burris, Funda Meric-Bernstam, Charles Swanton, and Christopher J. Sweeney.

Representative recent papers authored by John D. Hainsworth include:

  • "Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study", 2021, The Lancet Oncology
  • "Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study", 2022, The Lancet Oncology
  • "Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study", 2020, Annals of Oncology
  • "Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study", 2021, Cancer Discovery
  • "Cancer of Unknown Primary in the Molecular Era", 2021, Trends in cancer

John D. Hainsworth was recognized as a Fellow of the American Society of Mechanical Engineers in 2014.

Best Publications

  • BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER

    Herbert Hurwitz;Louis Fehrenbacher;William Novotny;Thomas Cartwright

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

  • Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

    Aleksandar Sekulic;Michael R. Migden;Anthony E. Oro;Luc Dirix

  • Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

    Marianne E Pavel;John D Hainsworth;Eric Baudin;Marc Peeters

  • Adjuvant docetaxel for node-positive breast cancer.

    Miguel Martin;Tadeusz Pienkowski;John R Mackey;Marek Pawlicki

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer

    Herbert I. Hurwitz;Louis Fehrenbacher;John D. Hainsworth;William Heim

  • Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

    Howard S. Hochster;Lowell L. Hart;Ramesh K. Ramanathan;Barrett H. Childs

  • Proposal for classifying the acute emetogenicity of cancer chemotherapy.

    Paul J. Hesketh;Mark G. Kris;Steven M. Grunberg;Thomas Beck

  • Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

    Carla Casulo;Michelle Byrtek;Keith L. Dawson;Xiaolei Zhou

  • Diagnostic and therapeutic management of cancer of an unknown primary

    N. Pavlidis;E. Briasoulis;J. Hainsworth;F.A. Greco

  • Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

    F M Muggia;J D Hainsworth;S Jeffers;P Miller

  • Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

    Frank A. Scappaticci;Louis Fehrenbacher;Thomas Cartwright;John D. Hainsworth

  • Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma

    John D. Hainsworth;Sharlene Litchy;Howard A. Burris;Daniel C. Scullin

  • Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma

    Margaret Tempero;William Plunkett;Veronique Ruiz Van Haperen;John Hainsworth

  • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

    Roy S Herbst;Rafat Ansari;Frederique Bustin;Patrick Flynn

  • Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

    John D. Hainsworth;Sharlene Litchy;John H. Barton;Gerry Ann Houston

  • Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network

    John D. Hainsworth;Sharlene Litchy;Don W. Shaffer;Van L. Lackey

  • Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase IIA multiple basket study

    John D. Hainsworth;Funda Meric-Bernstam;Charles Swanton;Herbert Hurwitz

Frequent Co-Authors

David R. Spigel
David R. Spigel Sarah Cannon Research Institute
F. Anthony Greco
F. Anthony Greco Sarah Cannon Research Institute
Howard A. Burris
Howard A. Burris Sarah Cannon Research Institute
David H. Johnson
David H. Johnson The University of Texas Southwestern Medical Center
Herbert Hurwitz
Herbert Hurwitz Duke University
Walter M. Stadler
Walter M. Stadler University of Chicago
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Jeffrey R. Infante
Jeffrey R. Infante Janssen (Belgium)
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Charles Swanton
Charles Swanton The Francis Crick Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t have to follow a traditional path. Many students expand their healthcare knowledge with flexible online degrees. For instance, those interested in preventive medicine and wellness can consider a nutrition degree online, which opens doors to roles in dietetics, public health, and health education.

For those focused on healthcare leadership and administration, accredited mha programs deliver essential business and management skills, qualifying graduates for managerial roles in hospitals and health systems.

Registered nurses can advance their careers efficiently through rn bsn online programs no clinicals, allowing working professionals to earn their bachelor’s without disrupting their schedules. Additionally, those seeking advanced clinical or leadership nursing roles may opt for accelerated dnp programs, which provide a fast-track to doctoral-level expertise.

Online healthcare degrees offer diverse pathways for career advancement and specialization—ideal for students at every stage of their medical journey.

Best Scientists Citing John D. Hainsworth

Trending Scientists

Recently Published Articles